L'ipertensione polmonare:come diagnosticarla e trattarlaASMaD
Presentazione a cura del Dottor Carmine Dario Vizza - XII° Congresso Nazionale FIMeG 2018 - The Silver Tsunami: l'anziano fra appropriatezza e farmaeconomia
This document discusses the treatment of pulmonary arterial hypertension (PAH), including:
- Approved PAH therapies such as endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostanoids.
- The three main pathways involved in PAH pathogenesis.
- Treatment recommendations for PAH associated with congenital heart disease, including the use of PAH-specific therapies.
- Evidence that PAH-specific therapies can reduce mortality in patients with Eisenmenger syndrome.
- Lung transplantation is an option for patients with inadequate response to maximal PAH therapy.
H trattamento dell’ipertensione arteriosa polmonareguch-piemonte
This document discusses the treatment of pulmonary arterial hypertension. Pulmonary arterial hypertension has several underlying causes, with the most common being idiopathic pulmonary arterial hypertension at around 50% of cases. Medications are the primary treatment and work to dilate blood vessels and improve heart function. These include endothelin receptor antagonists, phosphodiesterase type-5 inhibitors, prostanoids, and soluble guanylate cyclase stimulators. In severe cases, lung transplantation may be considered.
4. 2000
• Il 17-11-00 : take down Fontan +
atrioseptectomia + shunt (goretex 4 mm) tra
arteria e vena anonima
• Saturazione in postoperatorio 85-90%
2002
Cateterismo il 11-12-02: PAPm 15 mmHg
Sat O2 90%
2005
• Ottobre 2005 emoftoe recidivante
• Il 25-10-05 embolizzazione di collaterali al
polmone dx
• Il 26-10-05 CCE per flutter
• Terapia: cordarone + ASA
